These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
6. Dissociation of vasospasm-related morbidity and outcomes in patients with aneurysmal subarachnoid hemorrhage treated with clazosentan: a meta-analysis of randomized controlled trials. Shen J; Pan JW; Fan ZX; Xiong XX; Zhan RY J Neurosurg; 2013 Jul; 119(1):180-9. PubMed ID: 23641823 [TBL] [Abstract][Full Text] [Related]
8. Dissociation of vasospasm and secondary effects of experimental subarachnoid hemorrhage by clazosentan. Sabri M; Ai J; Macdonald RL Stroke; 2011 May; 42(5):1454-60. PubMed ID: 21454820 [TBL] [Abstract][Full Text] [Related]
9. Different effects of clazosentan on consequences of subarachnoid hemorrhage in rats. Chen G; Tariq A; Ai J; Sabri M; Jeon HJ; Tang EJ; Lakovic K; Wan H; Macdonald RL Brain Res; 2011 May; 1392():132-9. PubMed ID: 21466789 [TBL] [Abstract][Full Text] [Related]
10. An Update on the Efficacy and Safety Profile of Clazosentan in Cerebral Vasospasm After Aneurysmal Subarachnoid Hemorrhage: A Meta-Analysis. Song J; Xue YQ; Wang YJ; Xu P; Sun DK; Chen W World Neurosurg; 2019 Mar; 123():e235-e244. PubMed ID: 30496924 [TBL] [Abstract][Full Text] [Related]
11. Clazosentan: an endothelin receptor antagonist for treatment of vasospasm after subarachnoid hemorrhage. Macdonald RL Expert Opin Investig Drugs; 2008 Nov; 17(11):1761-7. PubMed ID: 18922111 [TBL] [Abstract][Full Text] [Related]
12. Clazosentan for patients with subarachnoid haemorrhage: lessons learned. Wong GK; Poon WS Lancet Neurol; 2011 Oct; 10(10):871; author reply 871-2. PubMed ID: 21939894 [No Abstract] [Full Text] [Related]
13. Thick and Diffuse Subarachnoid Blood as a Treatment Effect Modifier of Clazosentan After Subarachnoid Hemorrhage. Mayer SA; Aldrich EF; Bruder N; Hmissi A; Macdonald RL; Viarasilpa T; Marr A; Roux S; Higashida RT Stroke; 2019 Oct; 50(10):2738-2744. PubMed ID: 31394993 [TBL] [Abstract][Full Text] [Related]
14. Reversal of Vasospasm with Clazosentan After Aneurysmal Subarachnoid Hemorrhage: A Pilot Study. Higashida RT; Bruder N; Gupta R; Guzman R; Hmissi A; Marr A; Mayer SA; Roux S; Weidauer S; Aldrich EF World Neurosurg; 2019 Aug; 128():e639-e648. PubMed ID: 31054336 [TBL] [Abstract][Full Text] [Related]
16. Preventive Effect of Clazosentan against Cerebral Vasospasm after Clipping Surgery for Aneurysmal Subarachnoid Hemorrhage in Japanese and Korean Patients. Fujimura M; Joo JY; Kim JS; Hatta M; Yokoyama Y; Tominaga T Cerebrovasc Dis; 2017; 44(1-2):59-67. PubMed ID: 28463833 [TBL] [Abstract][Full Text] [Related]
17. Effect of clazosentan in patients with aneurysmal subarachnoid hemorrhage: a meta-analysis of randomized controlled trials. Wang X; Li YM; Li WQ; Huang CG; Lu YC; Hou LJ PLoS One; 2012; 7(10):e47778. PubMed ID: 23082215 [TBL] [Abstract][Full Text] [Related]
19. Clazosentan (AXV-034343), a selective endothelin A receptor antagonist, in the prevention of cerebral vasospasm following severe aneurysmal subarachnoid hemorrhage: results of a randomized, double-blind, placebo-controlled, multicenter phase IIa study. Vajkoczy P; Meyer B; Weidauer S; Raabe A; Thome C; Ringel F; Breu V; Schmiedek P J Neurosurg; 2005 Jul; 103(1):9-17. PubMed ID: 16121967 [TBL] [Abstract][Full Text] [Related]
20. Clazosentan for Aneurysmal Subarachnoid Hemorrhage: An Updated Meta-Analysis with Trial Sequential Analysis. Cho SS; Kim SE; Kim HC; Kim WJ; Jeon JP World Neurosurg; 2019 Mar; 123():418-424.e3. PubMed ID: 30508597 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]